Letter to the Editor: Reply to Zhao, Wu, and Ma

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.

Free article

Comment

Joao V Alessi et al. J Thorac Oncol. 2023 Jun.

Free article

. 2023 Jun;18(6):e61-e62.

doi: 10.1016/j.jtho.2023.03.018.

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.

No abstract available

Comment on

Clinical and Genomic Factors Predicting the Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Zhao B, Wu J, Ma W. Zhao B, et al. J Thorac Oncol. 2023 Jun;18(6):e59-e60. doi: 10.1016/j.jtho.2023.02.017. J Thorac Oncol. 2023. PMID: 37210183 No abstract available.